Merck Q1 2026 Performance: Growth and Innovations in Oncology and Cardiometabolic Care

Merck’s first-quarter 2026 results have been published and highlight key growth drivers, regulatory achievements, and strategic moves that reinforce the company’s diversified portfolio.

Oncology Dominance Fueled by KEYTRUDA Expansion

Merck Q1 2026 performance was primarily driven by its oncology franchise, with KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX sales reaching $8.0 billion, up 12% from the prior year. The subcutaneous formulation contributed $128 million in its early U.S. launch. Multiple regulatory wins strengthened its position, including FDA and European approvals for KEYTRUDA in PD-L1-positive platinum-resistant ovarian cancer, backed by overall survival data from the KEYNOTE-B96 trial. Positive Phase 3 results in muscle-invasive bladder cancer further support its use in earlier lines of therapy.

WINREVAIR Delivers Exceptional Cardiometabolic Growth

WINREVAIR (sotatercept-csrk) continued its rapid uptake, delivering $525 million in sales — an 88% increase — in its second full quarter on the market. New Phase 2 data in combined post- and precapillary pulmonary hypertension with heart failure with preserved ejection fraction demonstrated proof-of-concept, paving the way for a Phase 3 program. These advances in cardiometabolic and respiratory assets highlight Merck’s commitment to addressing high-burden chronic diseases.

Key Regulatory Wins in Infectious Disease

Merck secured FDA approval for IDVYNSO (doravirine/islatravir), the first two-drug, once-daily oral HIV-1 regimen that does not contain an integrase inhibitor. The European Commission also approved ENFLONSIA (clesrovimab) for prevention of RSV lower respiratory tract disease in infants. These approvals mark important progress in Merck Q1 2026 performance within the infectious disease portfolio.

Strategic Acquisitions Strengthen Future Pipeline

The company announced its agreement to acquire Terns Pharmaceuticals, adding a promising oral therapy for chronic myeloid leukemia. Combined with the earlier Cidara Therapeutics acquisition, these moves reflect Merck’s focus on bolstering its hematology and overall pipeline. Despite one-time charges impacting GAAP results, underlying business performance remained strong, leading Merck to narrow and raise its full-year 2026 sales and non-GAAP EPS guidance.

Value Implications for Market Access and HEOR

Merck Q1 2026 performance and its expanding labels across oncology, cardiometabolic disease, and infectious diseases carry important implications for health economics, pricing, and reimbursement. As utilization grows in earlier treatment settings, robust real-world evidence demonstrating survival benefits, reduced hospitalizations, and improved quality of life will be critical to maintaining strong payer coverage and favorable access.

Source